Page 16 - Read Online

Page 230 Mini et al. Cancer Drug Resist 2020;3:225-31 I http://dx.doi.org/10.20517/cdr.2020.10

Overall, the manuscripts included in this special issue underscore the relevance of germline and somatic
DNA variations in response (efficacy and toxicity) to pharmacological treatment in cancer. Examples
for which data have been already widely confirmed in several cancer types indicate that personalized
oncological treatments represent a fundamental goal to be further pursued in all other malignant
conditions and related cancer therapeutics.

DECLARATIONS
Acknowledgments
The Guest Editors gratefully acknowledge the relevant contribution to this monographic special issue of the
distinguished scientists invited to submit their valuable manuscripts to cover most of the current topics in
cancer pharmacogenetics and pharmacogenomics.

Authors’ contributions
Mini E and Nobili S equally contributed to the writing of this editorial.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Roden DM, McLeod HL, Relling MV, Williams MS, Mensah GA, et al. Pharmacogenomics. Lancet 2019;394:521-32.
2. Mini E, Nobili S. Pharmacogenetics: implementing personalized medicine. Clin Cases Miner Bone Metab 2009;6:17-24.
3. Wake DT, Ilbawi N, Dunnenberger HM, Hulick PJ. Pharmacogenomics: prescribing precisely. Med Clin North Am 2019;103:977-90.
4. Levitzki A, Klein S. My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer.
Proc Natl Acad Sci U S A 2019;116:11579-86.
5. Church D, Kerr R, Domingo E, Rosmarin D, Palles C, et al. ‘Toxgnostics’: an unmet need in cancer medicine. Nat Rev Cancer
2014;14:440-5.
6. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer
2013;13:714-26.
7. FDA. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). Available from: https://www.fda.gov/
media/119249/download [Last accessed on 12 Feb 2020]
8. EMA. Concept paper on predictive biomarker-based assay development in the context of drug development and lifecycle. Available
from: https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-predictive-biomarker-based-assay-development-
context-drug-development-lifecycle_en.pdf [Last accessed on 12 Feb 2020]
9. PharmGKB website. Available from: https://www.pharmgkb.org [Last accessed on 12 Feb 2020]
10. Kaehler M, Cascorbi I. Germline variants in cancer therapy. Cancer Drug Resist 2019;2:18-30.
11. Olivera G, Sendra L, José Herrero M, Berlanga P, Gargallo P, et al. Pharmacogenetics implementation in the clinics: information and
guidelines for germline variants. Cancer Drug Resist 2019;2:53-68.
12. Crisafulli C, Romeo PD, Calabrò M, Epasto LM, Alberti S. Pharmacogenetic and pharmacogenomic discovery strategies. Cancer Drug